Work

Practice patterns, gaps, and priorities in infection management for patients receiving bispecific antibodies and CAR-T cell therapy – Results from the E-Impact survey of the EHA-SWG infections in hematology

Year: 2026
Type: article
Study design: Observational Study
Abstract: Bispecific antibodies (BsAbs) and chimeric antigen receptor T-cell (CAR-T) therapies have transformed the treatment of hematologic malignancies, but infectious complications remain a leading cause of morbidity and mortality. We conducted a multicenter international survey across 101 institutions—predominantly academic tertiary hospitals (80.2%)—to characterize contemporary prevention and management practices. We assessed antimicrobial prophylaxis, infection surveillance, and management of therapy-induced immunodeficiency for patients receiving BsAbs and/or CAR-T. Practices were highly heterogeneous. According to respondents’ perception, viral infections were the most frequent with BsAbs (69.3%), whereas bacterial infections predominated after CAR-T (52.8%). Anti–Pneumocystis jirovecii prophylaxis was nearly universal (93.5% BsAbs; 97.5% CAR-T), but antibacterial and antifungal prophylaxis varied widely and were omitted in 86% and 38.7% of BsAb centers, respectively. CMV monitoring strategies differed markedly; one-third of BsAb centers did not routinely monitor CMV-DNA. Most respondents identified better guidelines (72.3% BsAbs; 52.8% CAR-T), improved diagnostic tools, and multidisciplinary approaches as priorities. These findings underscore substantial practice variation and the urgent need for harmonized, evidence-based guidance, particularly in light of recent data highlighting prolonged hypogammaglobulinemia, infection burden per patient-month with continuously dosed BsAbs, and the potential protective effect of immunoglobulin replacement. Prospective studies are warranted to define optimal prophylaxis, surveillance, and immunoglobulin replacement strategies in these populations.
Authors: Maria Stefania Infante, Livio Pagano, Sigrún Einarsdóttir, Oliver A. Cornely, Jon Salmanton-García, On behalf of E.-Impact investigators team, Toine Mercier, Nikola Pantic, Filippo Luciani, Rosanne Sprute, Pasquale Niscola, Eli Muchtar, Sapura Ibragimova, Koray Yalcin, Fabio Forghieri, Lucrecia Yañez San Segundo, Verena Petzer, Boudhayan Bhattacharjee, Guldane Cengiz Seval, Juan Pablo Cabrera Guerrero, Adoración Egido González, Syed Abdullah, Abubakar Mursal, Martin Čerňan, Fabiana Dellai, Soumyadip Chatterji, Nazish Arshad, Nuno Lacerda Principe, Milan Navratil, Giovanna Travi, Ioanna Sakellari, Terenzio Cosio, Chidiebere Promise Ndubueze, Zlate Stojanoski, Adrien De Voeght, Sanjay Bhattacharya, Andreea-Lacramioara Mohorea-Neata, Jiri Sramek, Raluca Papagheorghe, Ulrich Jaeger, Nikolaos Syrmos, Rogelio de Jesús Treviño-Rangel, Mathias Brehon, Manuela Spadea, Alexey Maximov, Manuela Aguilar-Guisado, Annarosa Cuccaro, Qing Cao, Christian Bjørn Poulsen, Claudio Cerchione, Margherita Malchiodi, Arda Isik, Abubakar Gwarzo, Alberto García-Salido, Vanesa Alende Castro, Dafna Yahav, Carolina Miranda Castillo, Maria Kourti, Eleni Gavriilaki, Sonia Pi Ruano, Francesca Farina, Guillaume Dachy, Paloma Merino Amador, Ana María González, Mario Virgilio Papa, Lubos Drgona, Luca Montanari, José Ángel Hernández Rivas, Jakob Passweg, Andreas H. Groll, Mi Zhou, Jens Van Praet, Angela Loizidou, Barbora Weinbergerová, Ildefonso Espigado, Daniel Gil-Alós, Eduarda Pena, Elena Rossi, Julien Gras, Roberta Della Pepa, Delia Monica Dima, Alessandro Busca, Nicola Sgherza, Nargiza Babakhanova, Alejandro Díaz Díaz, Rui Bergantim, Avinash Aujayeb, Bahar Incu Ulu, Guillemette Fouquet, Andrea Murtas, Raeseok Lee, Marcio Nucci, Fernando Escalante, Beatrice Anna Zannetti, Habip Gedik, Toni Valković, Charikleia Kelaidi, Stephen Ogbere, Lorenzo Chiusaroli, Antonija Verhaz, Luca Cupelli, Josia Fauser, Zaira Raquel Palacios Baena, Andrea Gutiérrez Villanueva, Jung-ah Kim, Alexander Puzik, Chizaram Anselm Onyeaghala, Marta Sitges, Natasha Ali, Gülhadiye Avcu, Alejandro Avendaño, Wing Y. Au, Nick Alexander De Jonge
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,590
OpenAlex ID: W7196941449
FWCI:
Cites: 15
Cited by:
Related to: 10